Alfred Health Radiation Oncology, Melbourne, Victoria, Australia.
Central Clinical School, Monash University, Melbourne, Victoria, Australia.
Asia Pac J Clin Oncol. 2023 Feb;19(1):149-157. doi: 10.1111/ajco.13783. Epub 2022 May 22.
To evaluate the patterns of use of different radiation therapy (RT) fractionation for multiple myeloma (MM) bone disease.
This is a population-based cohort of patients with MM who had RT between 2012 and 2017 as captured in the statewide Victorian Radiotherapy Minimum Data Set in Australia. Data linkage was performed to identify subsets of RT delivered within 3 months of death. RT fractionation was classified into four groups: single-fraction (SFRT), 2-5, 6-10, and > 10 fractions. Changes in RT fractionation use over time were evaluated with the Cochran-Armitage test for trend. Factors associated with RT fractionation were evaluated using multivariate logistic regressions.
Nine hundred and sixty-seven courses of RT were delivered in 623 patients. The proportion of SFRT, 2-5, 6-10 and > 10 fractions RT was 18%, 47%, 28%, and 7%, respectively. There was an increase in the use of 2-5 fractions, from 48% in 2012 to 60% in 2017 (p-trend < .001), with corresponding decrease in the use of 6-10 fractions, from 26% in 2012 to 20% in 2017 (p-trend = .003). Nine percent (40/430) of RT courses at private institutions were SFRT, compared to 25% (135/537) in public institutions (p < .001). In multivariate analyses, treatment in private institution was the strongest predictor of multifraction RT use. SFRT use was more common closer to the end of life-18%, 14%, and 33% of RT within 2-3, 1-2, < 1 month of death, respectively.
There is increasing use of shorter course RT (2-5 fractions) for MM over time. SFRT use remains low, with large variation in practice.
评估多发性骨髓瘤(MM)骨病不同放疗分割方式的使用模式。
本研究为基于人群的 MM 患者队列,这些患者在 2012 年至 2017 年间接受了放疗,数据来源于澳大利亚全州范围内的维多利亚放疗最低数据集。进行了数据链接,以确定在死亡后 3 个月内进行的放疗亚组。将放疗分割分为 4 组:单次分割(SFRT)、2-5 次、6-10 次和>10 次。使用 Cochran-Armitage 趋势检验评估 RT 分割使用随时间的变化。使用多变量逻辑回归评估与 RT 分割相关的因素。
共为 623 例患者提供了 967 次放疗。SFRT、2-5 次、6-10 次和>10 次分割 RT 的比例分别为 18%、47%、28%和 7%。2-5 次分割的使用率增加,从 2012 年的 48%增加到 2017 年的 60%(趋势检验 p<0.001),而 6-10 次分割的使用率相应下降,从 2012 年的 26%下降到 2017 年的 20%(趋势检验 p=0.003)。在私立机构中,9%(40/430)的放疗课程为 SFRT,而在公立医院中,这一比例为 25%(135/537)(p<0.001)。在多变量分析中,在私立机构治疗是接受多分割 RT 治疗的最强预测因素。SFRT 更常用于接近生命末期-在死亡前 2-3、1-2、<1 个月内,分别有 18%、14%和 33%的 RT 为 SFRT。
随着时间的推移,多发性骨髓瘤的放疗分割方式越来越短(2-5 次分割)。SFRT 的使用率仍然较低,且实践中存在较大差异。